-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$1.00170.27% Upside
Cyclacel Pharmaceuticals, Inc. Frequently Asked Questions
-
What analysts cover Cyclacel Pharmaceuticals, Inc.?
Cyclacel Pharmaceuticals, Inc. has been rated by research analysts at Roth Capital in the past 90 days.